Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 22, 2024 3:16pm
214 Views
Post# 36052573

The evidence is very clear, buy Onc…

The evidence is very clear, buy Onc…

One of our on- going FUDsters states " the evidence is clear, sell ONC"
yet, does not mention, detail or offer that evidence.
Reminds me of Trump & his fake news mantra.
moving on.....evidence, why to buy?

in the previous 30-90 days Onc has had some very compelling evidence!
Most recent a firm endorsement from CGAR , to assist oncolyitics biotech , into a phase 3 trial, for cohort #1, of the Gobblet trial, l alongside co- therapy with Roche.
Just before that, they announced an additional cohort , funded by the PanCan Foundation, for $5million.A piece of factual evidence.
They additionally announced a meeting with FDA to accelerate the MBc trial, phase 3 , allowing various variables previously not part if the MBc trial. 

That answer & thusly the outline/ details of MBc phase 3 trial is expected wining the next few weeks.
Not having an exact date, is not evidence of anything. Being positive or negative.
Prolamining one should sell, because there is no date......beyond baseless.
Claiming " no date" is evidence to sell, beyond silly.
comparing oncs record compared to other biotechs? as evidence?
A quick research indicates that 7.9% of new products actually get to market.
Meaning almost 92% of all biotech new products fail!
evidence?
onc has huge clinical support from FDA, CGAR, Roche, Pfizer & others.
both financial, technical & product co- therapy support.
So, no date?
Not imho reason to sell or buy. Just random information.
regards.
 

<< Previous
Bullboard Posts
Next >>